<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03286517</url>
  </required_header>
  <id_info>
    <org_study_id>QuaideAzamU</org_study_id>
    <nct_id>NCT03286517</nct_id>
  </id_info>
  <brief_title>Link Between the Sensitivity of Kisspeptin Signalling and Pubertal Onset in Boys.</brief_title>
  <official_title>Changes in the Responsiveness of the Hypothalamic-pituitary-gonadal (HPG) Axis to Kisspeptin-10 Administration During Pubertal Transition in Boys</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ghulam Nabi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Quaid-e-Azam University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific objective of this study was to investigate the sensitivity of Kisspeptin
      receptor 1 (KISS1R) by determining the responsiveness of GnRH neuron to kisspeptin
      administration across the pubertal stages and adult group through measuring plasma LH
      (luteinizing hormone) and testosterone concentrations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No studies in humans are available regarding KISS1R signalling that, whether expression of
      the KISS1 or KISS1R sensitivity increases during the pubertal transition in boys. Kisspeptin
      regulates HPG (hypothalamic pituitary gonadal) axis by secreting GnRH that acts on the
      pituitary gonadotrophs to secrete LH and FSH. But in contrast to pubertal period, juvenile
      period kisspeptin pulsatility is reduced, that leads to low GnRH pulsatility and low level of
      plasma LH, FSH and testosterone. The objective of this study was to determine the response of
      exogenous kisspeptin in various juvenile stages up to puberty and also in the adults by
      measuring the level of plasma LH and testosterone. This study would help us to determine that
      whether there is any link between the increased sensitivity of kisspeptin signalling and
      puberty onset?, Or at what Tanner stage pre pubertal boys enter into puberty.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 2014</start_date>
  <completion_date type="Actual">March 5, 2015</completion_date>
  <primary_completion_date type="Actual">August 8, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All the groups were injected with exogenous IV kisspeptin according to the body weight.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>All the participants were told for injecting the kisspeptin.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the sensitivity of KISS1R by determining the responsiveness of GnRH neuron to kisspeptin administration across the pubertal stages and adult group through measuring plasma luteinizing hormone and testosterone concentrations</measure>
    <time_frame>A time frame for each individual was 3 hours. Kisspeptin-10 was injected intravenously and the blood samples were collected at 30 minutes intervals for 30 minutes pre and 2 hours post kisspeptin-10 injection through cannula.</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Reproductive Physiological Phenomena</condition>
  <arm_group>
    <arm_group_label>Tanner Stage I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 9.5 µg/BW.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tanner Stage II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 11.50 µg/BW.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tanner Stage III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 12.67 µg/BW.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tanner Stage IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 15.11 µg/BW.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tanner stage V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 20.5 µg/BW.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 1 µg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)</intervention_name>
    <description>A neurohormone</description>
    <arm_group_label>Tanner Stage I</arm_group_label>
    <arm_group_label>Tanner Stage II</arm_group_label>
    <arm_group_label>Tanner Stage III</arm_group_label>
    <arm_group_label>Tanner Stage IV</arm_group_label>
    <arm_group_label>Tanner stage V</arm_group_label>
    <arm_group_label>Adult Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Boys were classified into 5 different Tanner stages (I-V) according to the criteria of
             Feingold D. In Atlas of physical diagnosis. Pediatric endocrinology. 2nd ed.
             Philadelphia. WB Saunders; 1992, pp. 16-19. For comparison, adult men were also
             recruited.

        Exclusion Criteria:

          -  Individuals with chronic illness or disorder, i.e. hepatic and renal complications,
             epilepsy, pneumonia, asthma, orchitis, hernia, cryptorchidism, mental retardation,
             etc. were excluded from this study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>children were classified into five pubertal stages called Tanner stages on the basis of a genital examination by a physician.</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammad Shahab, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Quaid-i-Azam University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quaid-i-Azam University</name>
      <address>
        <city>Islamabad</city>
        <zip>45320</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <reference>
    <citation>Mead EJ, Maguire JJ, Kuc RE, Davenport AP. Kisspeptins are novel potent vasoconstrictors in humans, with a discrete localization of their receptor, G protein-coupled receptor 54, to atherosclerosis-prone vessels. Endocrinology. 2007 Jan;148(1):140-7. Epub 2006 Oct 5.</citation>
    <PMID>17023533</PMID>
  </reference>
  <results_reference>
    <citation>Jayasena CN, Nijher GM, Comninos AN, Abbara A, Januszewki A, Vaal ML, Sriskandarajah L, Murphy KG, Farzad Z, Ghatei MA, Bloom SR, Dhillo WS. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab. 2011 Dec;96(12):E1963-72. doi: 10.1210/jc.2011-1408. Epub 2011 Oct 5.</citation>
    <PMID>21976724</PMID>
  </results_reference>
  <results_reference>
    <citation>Jayasena CN, Nijher GM, Chaudhri OB, Murphy KG, Ranger A, Lim A, Patel D, Mehta A, Todd C, Ramachandran R, Salem V, Stamp GW, Donaldson M, Ghatei MA, Bloom SR, Dhillo WS. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009 Nov;94(11):4315-23. doi: 10.1210/jc.2009-0406. Epub 2009 Oct 9.</citation>
    <PMID>19820030</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2017</study_first_submitted>
  <study_first_submitted_qc>September 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2017</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Quaid-e-Azam University</investigator_affiliation>
    <investigator_full_name>Ghulam Nabi</investigator_full_name>
    <investigator_title>Mr.</investigator_title>
  </responsible_party>
  <keyword>Puberty, Sexuality</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual response to kisspeptin administration without disclosing the identity of an individual can be shared with other researchers.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Any information required can be provided</doc_type>
      <doc_url>http://www.qau.edu.pk/profile.php?id=802001</doc_url>
      <doc_comment>Prof. Muhammad Shahab will provide the information upon request.</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

